CVE:HLS - HLS Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$14.27 +0.23 (+1.64 %)
(As of 01/15/2019 04:00 PM ET)
Previous CloseC$14.04
Today's RangeC$14.07 - C$14.29
52-Week RangeC$7.69 - C$16.75
Volume10,481 shs
Average Volume221,337 shs
Market CapitalizationN/A
P/E Ratio-14.68
Dividend Yield1.42%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone647-495-9000

Debt

Current Ratio0.84
Quick Ratio0.75

Price-To-Earnings

Sales & Book Value

Annual SalesC$65.13 million
Price / Sales5.98
Cash FlowC$0.37 per share
Price / Cash Flow38.68
Book ValueC$6.11 per share
Price / Book2.33

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees43
OptionableNot Optionable

HLS Therapeutics (CVE:HLS) Frequently Asked Questions

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS."

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc (CVE:HLS) released its earnings results on Thursday, November, 15th. The company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The firm had revenue of $19.97 million for the quarter, compared to analysts' expectations of $20.85 million. View HLS Therapeutics' Earnings History.

When is HLS Therapeutics' next earnings date?

HLS Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for HLS Therapeutics.

Has HLS Therapeutics been receiving favorable news coverage?

Media stories about HLS stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. HLS Therapeutics earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of HLS Therapeutics' key competitors?

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the folowing people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)
  • Mr. Gilbert Godin, Pres & COO (Age 59)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)
  • Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50)

How do I buy shares of HLS Therapeutics?

Shares of HLS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$14.27.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is http://www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.


MarketBeat Community Rating for HLS Therapeutics (CVE HLS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  57
MarketBeat's community ratings are surveys of what our community members think about HLS Therapeutics and other stocks. Vote "Outperform" if you believe HLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel